Navigation Links
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Date:11/8/2007

velop, manufacture, license and sell its

products or product candidates;

* the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

* the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

* the adequacy of the Company's patents and proprietary rights;

* the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

* the Company's ability to retain compliance with the NASDAQ's listing

qualifications; and

* the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Brian Korb

The Trout Group

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
3. New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid-Induced Bowel Dysfunction in Patients With Chronic Severe Pain
4. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
5. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
6. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
7. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
8. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
9. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... , August 3, 2015 ... Study on 3D Cell Culture: Asia ... Persistence Market Research, the global 3D cell culture market was valued ... to expand at a CAGR of 29.1% to account ... Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp 3D ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... and quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC ... method “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... alarming pace, a University of Central Florida research team is ... a miniature diagnostic toolkit in the hopes of stimulating earlier ... the National Science Foundation for up to $600,000 over three ... of a credit card to detect damaging levels of oxygen ...
... Protection Agency today outlined a new research strategy ... human health and the environment. Nanomaterials are materials ... A nanometer is approximately 1/100,000 the width of ... in hundreds of consumer products, including sunscreen, cosmetics ...
... ... new ClearTrial TRACK provides integrated planning, outsourcing, project tracking, reforecasting, accrual management, and ... ... www.cleartrial.com ), the leading provider of Clinical Trial Operations (CTO) software, announced today ...
Cached Biology Technology:UCF team developing tool kit to help diagnose dementia 2EPA announces research strategy to study nanomaterials 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 2ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 3ClearTrial Launches Industry-first Software Platform for Integrating Clinical Trial Operations from Plan to Cash™, Driving Operational Efficiencies and Accelerating Clinical Development 4
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... -- Die 10. internationale Konferenz zu Genomik (ICG-10, ... findet vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ... die ICG weltweit zu einem der einflussreichsten jährlichen ... der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/27/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Huawei has selected the Synaptics ® ... stylish smartwatch. Huawei chose the state-of-the-art ClearPad capacitive ... and highly responsive human interface qualities such as ... required a classic round watch face and Synaptics ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... the human mind in the hope of answering some ... to the nature of knowledge. Today cognitive scientists link ... research in various areas, an approach epitomized by WIREs ... The content of this journal will be free for ...
... Iowa - Research at Iowa State University has led scientists ... and eventually kills them. A research team led by Gaya ... had previously solved the structure of a critical part of ... host immune suppression. Amarasinghe and his research team now know ...
... GAINESVILLE, Fla. The University of Florida,s Institute on ... National Institutes of Health to construct an almost 40,000-square-foot ... building will bring together scientists from a range of ... out on the campus. "This is a unique ...
Cached Biology News:Iowa State University researcher discovers Ebola's deadly secret 2UF gets almost $15 million in federal funds to build research complex to help older adults 2UF gets almost $15 million in federal funds to build research complex to help older adults 3
...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
... mixed TAMRA isomers are predominantly used for ... preferred for labeling peptides and nucleotides because ... that is often required in the conjugation ... 6-TAMRA for labeling peptides and proteins. 6-TAMRA ...
Biology Products: